THMO Overview

ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. It provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and the CAR-TXpress platform for large scale cell manufacturing services. Its products include Clinical Bio-Banking Applications, Point-of-Care Applications and Large-Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications include AXP Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large-Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory use and CAR-TXpress Platform for Clinical Manufacturing. AXP Automated Cell Separation System is an automated, fully closed cell separation system.

Wall Street analysts forecast THMO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for THMO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Thermogenesis Holdings Inc revenue for the last quarter amounts to 2.74M USD, increased 6.42 % YoY.

Thermogenesis Holdings Inc. EPS for the last quarter amounts to -0.46 USD, decreased -88.70 % YoY.

Thermogenesis Holdings Inc (THMO) has 40 emplpoyees as of January 17 2026.

Today THMO has the market capitalization of 0.00 USD.